Phase II Trial of Veliparib in Patients with Previously-Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma

PURPOSE: BRCA-associated cancers have increased sensitivity to PARP inhibitors (PARPi). This single arm, non-randomized, multicenter phase II trial evaluated the response rate of velparib in patients with previously-treated BRCA1/2 or PALB2 mutant pancreatic adenocarcinoma (PDAC). METHODS: Patients...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur J Cancer
Main Authors: Lowery, Maeve A., Kelsen, David P., Capanu, Marinela, Smith, Sloane C., Lee, Jonathan W., Stadler, Zsofia K, Moore, Malcolm J, Kindler, Hedy L., Golan, Talia, Segal, Amiel, Maynard, Hannah, Hollywood, Ellen, Moynahan, MaryEllen, Salo-Mullen, Erin E., Kinh Gian Do, Richard, Chen, Alice P., Yu, Kenneth H., Tang, Laura H., O’Reilly, Eileen M.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7351022/
https://ncbi.nlm.nih.gov/pubmed/29223478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2017.11.004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares